Polymorphisms associated with adalimumab and infliximab response in moderate-to-severe plaque psoriasis
Entity
UAM. Departamento de Farmacología; UAM. Instituto Teófilo Hernando de I+D del Medicamento (ITH); Instituto de Investigación del Hospital de La Princesa (IP)Publisher
Future MedicineDate
2017-12-01Citation
10.2217/pgs-2017-0143
Pharmacogenomics 19.1 (2018): 7-16
ISSN
1462-2416 (print); 1744-8042 (online)DOI
10.2217/pgs-2017-0143Editor's Version
https://doi.org/10.2217/pgs-2017-0143Subjects
Adalimumab; Anti-TNF drugs; Infliximab; Pharmacogenetics; Psoriasis; FarmaciaRights
© 2018 Future Medicine Ltd.Abstract
Aims. This study evaluated the influence of pharmacogenetics in psoriatic patients treated with adalimumab and/or infliximab. Materials & methods: Prospective observational study evaluating the association of 124 polymorphisms with the response to adalimumab or infliximab (PASI75) in patients with moderate-to-severe plaque psoriasis at 3 months (n = 95) and 6 months of treatment (n = 90). Significant SNPs for univariate analysis were subjected to multivariate analysis. Results: Five SNPs were associated with PASI75 at 3 months: rs6661932 (IVL), rs2546890 (IL-12B), rs2145623 (NFKBIA), rs9304742 (ZNF816A) and rs645544 (SLC9A8). Furthermore, rs1061624 (TNFR1B) was associated with PASI75 at 6 months. Conclusion: Nevertheless, these biomarkers should be validated in large-scale studies before implementation in clinical practice.
Files in this item
Google Scholar:Ovejero-Benito, María C.
-
Prieto-Pérez, Rocío
-
Llamas-Velasco, Mar
-
Muñoz-Aceituno, Ester
-
Reolid, Alejandra
-
Saiz-Rodríguez, Miriam
-
Belmonte, Carmen
-
Román, Manuel
-
Ochoa Mazarro, María Dolores
-
Talegón, María
-
Cabaleiro, Teresa
-
Daudén Tello, Esteban
-
Abad Santos, Francisco